RTP Mobile Logo
Select Publications

Addeo A et al. COVID-19 and lung cancer: Risks, mechanisms and treatment interactions. J Immunother Cancer 2020;8(1):e000892. Abstract

Banna G et al. How we treat patients with lung cancer during the SARS-CoV-2 pandemic: primum non nocere. ESMO Open 2020;5(2):e000765. Abstract

Bilkhu R, Bille A. Elective lung cancer surgery in the COVID-19 era: How do we do it? Tumori 2020;[Online ahead of print]. Abstract

Bonomi L et al. A rapid fatal evolution of coronavirus disease-19 (COVID-19) in an advanced lung cancer patient with a long time response to nivolumab. J Thorac Oncol 2020;15(6):e83-e85. Abstract

Cafarotti S. Severe acute respiratory syndrome-coronavirus-2 infection and patients with lung cancer: The potential role of interleukin-17 target therapy. J Thorac Oncol 2020:S15560864(20)30330-0. Abstract

Calabro L et al. Challenges in lung cancer therapy during the COVID-19 pandemic. Lancet Respir Med 2020;8(6):542-4. Abstract

Davis AP et al. COVID-19: The use of immunotherapy in metastatic lung cancer. Immunotherapy 2020;12(8):545-8. Abstract

de Marinis F et al. Results of multilevel containment measures to better protect lung cancer patients from COVID-19: The IEO model. Front Oncol 2020;10:665. Abstract

Di Noia V et al. Immune checkpoint inhibitors in SARS-CoV-2 infected cancer patients: The spark that ignites the fire? Lung Cancer 2020;145:208-10. Abstract

Dingemans AC et al. Treatment guidance for patients with lung cancer during the coronavirus 2019 pandemic. J Thorac Oncol 2020;15(7):1119-36. Abstract

Faivre-Finn C et al. Reduced fractionation in lung cancer patients treated with curative-intent radiotherapy during the COVID-19 pandemic. Clin Oncol (R Coll Radiol) 2020;32(8):481-9. Abstract

Guckenberger M et al. Practice recommendations for lung cancer radiotherapy during the COVID-19 pandemic: An ESTRO-ASTRO consensus statement. Int J Radiat Oncol Biol Phys 2020;107(4):631-40. Abstract

Guo H et al. Challenges and countermeasures of thoracic oncology in the epidemic of COVID-19. Transl Lung Cancer Res 2020;9(2):337-47. Abstract

Kong Q et al. Analysis of the susceptibility of lung cancer patients to SARS-CoV-2 infection. Mol Cancer 2020;19(1):80. Abstract

Kumar S et al. Alternative multidisciplinary management options for locally advanced NSCLC during the coronavirus disease 2019 global pandemic. J Thorac Oncol 2020;15(7):1137-46. Abstract

Luo J et al. Impact of PD-1 blockade on severity of COVID-19 in patients with lung cancers. Cancer Discov 2020;[Online ahead of print]. Abstract

Roschewski M et al. Inhibition of Bruton tyrosine kinase in patients with severe COVID-19. Sci Immunol 2020;5(48):eabd0110. Abstract

Sereno M et al. A favorable outcome of pneumonia COVID 19 in an advanced lung cancer patient with severe neutropenia: Is immunosuppression a risk factor for SARS-COV2 infection? Lung Cancer 2020;145:213-5. Abstract

Singh AP et al. Management of lung cancer during the COVID-19 pandemic. JCO Oncol Pract 2020;[Online ahead of print]. Abstract

Sud A et al. Collateral damage: The impact on outcomes from cancer surgery of the COVID-19 pandemic. Ann Oncol 2020;[Online ahead of print]. Abstract

Tian J et al. Clinical characteristics and risk factors associated with COVID-19 disease severity in patients with cancer in Wuhan, China: A multicentre, retrospective, cohort study. Lancet Oncol 2020;21(7):893-903. Abstract

Thoracic Surgery Outcomes Research Network Inc. COVID-19 guidance for triage of operations for thoracic malignancies: A consensus statement from Thoracic Surgery Outcomes Research Network. Ann Thorac Surg 2020;[Online ahead of print]. Abstract

Zhao Z et al. Recommendations of individualized medical treatment and common adverse events management for lung cancer patients during the outbreak of COVID-19 epidemic. Thorac Cancer 2020;11(6):1752-7. Abstract